Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients

Patricia Moya, Juliana Salazar, María Jesús Arranz, César Díaz-Torné, Elisabeth Del Río, Jordi Casademont, Hèctor Corominas, Montserrat Baiget

Research output: Contribution to journalArticleResearchpeer-review

26 Citations (Scopus)

Abstract

© 2016 Future Medicine Ltd. Background: Methotrexate (MTX) is the most used drug for the treatment of rheumatoid arthritis (RA) although outcome differs among patients. Aim: To evaluate whether polymorphisms in pharmacokinetic genes are associated with outcome in RA patients receiving MTX. Patients & methods: We analyzed 28 SNPs in SLC19A1/RFC1, ABCB1, FPGS and GGH genes. Results: We studied 194 RA patients receiving MTX monotherapy. Two FPGS SNPs, rs10987742 and rs10106, were associated with response (p = 0.033 and p = 0.041, respectively). The FPGS rs10106 variant was also associated with MTX survival (p = 0.005) and toxicity (p = 0.021). Three ABCB1 SNPs, rs868755, rs10280623 and rs1858923, were associated with toxicity (p = 0.025, p = 0.048 and p = 0.031, respectively). Conclusion: FPGS and ABCB1 genetic variants can influence the outcome in RA patients receiving MTX monotherapy.
Original languageEnglish
Pages (from-to)11-25
JournalPharmacogenomics
Issue number1
DOIs
Publication statusPublished - 1 Jan 2016

Keywords

  • ABCB1
  • FPGS
  • GGH
  • methotrexate
  • pharmacogenetics
  • rheumatoid arthritis
  • SLC19A1/RFC1

Fingerprint

Dive into the research topics of 'Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients'. Together they form a unique fingerprint.

Cite this